The CooperCOO +3.13%84 Receivables Turnover is 1.34 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 84/100 and a GF Value™ of $101.02 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 812 Medical Devices & Instruments companies, The Cooper ranks worse than 54.06% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. The Cooper's Revenue for the
three
months ended in Apr. 2026 was $1,082 Mil. The Cooper's average Accounts Receivable for the
three
months ended in Apr. 2026 was $808 Mil.
Hence, The Cooper's Receivables Turnover for the
three
months ended in Apr. 2026 was 1.34.
The Cooper (NAS:COO) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
The Cooper Receivables Turnover Related Terms
The Cooper Receivables Turnover Historical Data
* Premium members only.
The historical data trend for The Cooper's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where The Cooper's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a Receivables Turnover of 1.34 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #439 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 54.1%.
Is The Cooper's Receivables Turnover too high?
The Cooper's current Receivables Turnover is 1.34. The Medical Devices & Instruments industry median Receivables Turnover is 5.53. The Cooper's value of 1.34 is 75.8% below this industry median. Based on the distribution chart, The Cooper ranks #439 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Receivables Turnover compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #439 out of 812 companies for Receivables Turnover. This places The Cooper in the lower half of its industry. The industry median Receivables Turnover is 5.53. The Cooper's value of 1.34 is 75.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.53, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Receivables Turnover of 1.34 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Receivables Turnover is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.02, compared to a current price of $74.20 — trading 26.5% below its estimated fair value. The current Receivables Turnover is 1.34 and 75.8% below the Medical Devices & Instruments industry median of 5.53. The Cooper's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For The Cooper (COO), the current Receivables Turnover is 1.34 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $74.20 is trading 26.5% below its estimated GF Value™ of $101.02.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Receivables Turnover: 1.34
GF Value™: $101.02 vs. price of $74.20 (26.5% below fair value)
Industry Position: 75.8% below the Medical Devices & Instruments median (#439 of 812)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
84GF Score
Get the complete analysis for COO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
